[A19-91] Pomalidomide (multiple myeloma) - Addendum to Commission A19-50
Last updated 05.12.2019
Commission awarded on 29.10.2019 by the Federal Joint Committee (G-BA).
Adults with multiple myeloma who have received at least one prior treatment regimen including lenalidomide
Conclusion of dossier assessment A19-50 unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A19-50||Pomalidomide (multiple myeloma) - Benefit assessment according to §35a Social Code Book V||Commission completed|